Mercodia was looking to investigate and assess new markets to achieve growth while maintaining product and service quality standards at their renowned high level, that has positioned them as a trusted brand on the Biotech market. Challenged with extended time to market due to extensive regulatory and quality demands, Mercodia needed a structured, evidence-based approach to evaluate potential markets that met their growth requirements.
BearingPoint created a cross-functional team of subject matter experts in academic research, medicine and life science knowledge and experts in strategic projects. Leveraging the Ansoff matrix, they organized workshops using an outside-in approach and an evidence-driven analysis of new disease areas. This resulted in a limited number of areas and markets. To reduce this number, they made a selection criteria framework tailored to fit the bio-tech industry and meet Mercodia’s requirements. Key opinion leaders in clinical trials were then interviewed to prepare a detailed competitive landscape.
Based on the BearingPoint contribution, Mercodia decided to pursue a new research market. BearingPoint’s assistance helped Mercodia obtain sufficient information and data to convince them to support a new research market leading to market differentiation and potential growth.
Founded in 1991 as a privately-owned biotech company, Mercodia is a world-leading developer, manufacturer and distributor of high-quality immunoassay kits for the measurement of biomarkers in the areas of diabetes, obesity and cardiovascular disease.